Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.
October 13, 2022
Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding
October 13, 2022 —  Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational…
Read More
The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines
October 12, 2022
Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution
October 12, 2022 —   Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month…
Read More
Study investigates metformin and other candidate drugs through a network medicine approach
October 12, 2022
Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research
October 12, 2022 —  Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible…
Read More
Renowned Stanford Cardiologist Brings Deep Clinical, Research, and Industry Expertise to Executive Team
October 12, 2022
HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer
October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG…
Read More
Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.
October 11, 2022
ELANA Heart Bypass Solution Shows Promising Preliminary Results in First-in-Human Trials
October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass…
Read More
Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.
October 11, 2022
Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes
October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain…
Read More
Grant Proceeds Will Support Pre-Clinical Studies
October 11, 2022
Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease
October 11, 2022 —  Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it…
Read More
Kyle Walsh, MD
October 07, 2022
Identifying How Inflammation Affects Stroke Recovery
October 7, 2022 — A new research grant will enable University of Cincinnati researchers to learn more about how…
Read More
This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research
October 07, 2022
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
October 7, 2022 — ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed…
Read More
Ultromics, a digital health technology company pioneering the development of transformative heart failure diagnostics, has joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP HF) including the National Institutes of Health (NIH) and the National Heart Lung and Blood Institute (NHLBI), managed by the Foundation for the National Institutes of Health (FNIH).
October 07, 2022
Ultromics joins FNIH Partnership to Transform Heart Failure Detection
October 7, 2022 —  Ultromics, a digital health technology company pioneering the development of transformative heart…
Read More
Rutgers study finds post-surgical hospitalization rates from left ventricular assist devices varied by socioeconomic factors
October 06, 2022
Lower-Income Patients with Heart Pumps More Likely Hospitalized with Major Bleeding, Infection or Heart Failure
October 6, 2022 —  The complications experienced by heart failure patients implanted with a left ventricular assist…
Read More
Research collaboration involving NYU Tandon School of Engineering, NYU Langone and the Food and Drug Administration will focus on biomarker data to improve performance analysis of stroke rehabilitation equipment. Image credit: Shidlovski
October 06, 2022
NYU Researchers Partner with FDA to Identify Biomarkers for Stroke Rehabilitation
October 6, 2022 —  Stroke is the leading cause of age-related motor disabilities and is becoming more prevalent in…
Read More
OpSens Inc. has announced that it has received 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA) for the SavvyWire, its new guidewire for transcatheter aortic valve replacement (TAVR) procedures.
October 06, 2022
OpSens Announces FDA Clearance for the SavvyWire for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures
October 6, 2022 – OpSens Inc., a Quebec-based medical device cardiology-focused company, has announced that it has…
Read More
Results presented at the Heart Failure Society of America Annual Scientific Meeting
October 06, 2022
Cleveland Clinic-Led Trial Finds That Increasing Salt Intake Does Not Affect Patients Hospitalized with Congestive Heart Failure During Treatment
October 6, 2022 —  Findings from a Cleveland Clinic-led trial show that increasing the salt intake by mouth for…
Read More
The American Society of Echocardiography (ASE) is targeting its research funding over the next five years to help solve some of the mysteries around the early detection of a common form of heart failure.
October 05, 2022
American Society of Echocardiography Invests in Joint Research Initiative to Help Patients Suffering from Wide-Reaching Form of Heart Failure
October 5, 2022 —  The American Society of Echocardiography (ASE) is targeting its research funding over the next five…
Read More
CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session
October 05, 2022
CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions
October 5, 2022 —  CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from…
Read More
Dr. Rakesh Arora to lead cardiac intensive care units and cardiac surgery research
October 05, 2022
UH Harrington Heart & Vascular Institute Recruits Renowned Cardiac Surgeon from Canada
October 5, 2022 —  University Hospitals (UH) Harrington Heart & Vascular Institute has a rich history of providing…
Read More
During the Heart Failure Society of America (HFSA) 2022 Scientific Meeting, Daxor Corporation announced new data from multiple studies validating the benefits of the company’s BVA-100 blood test for patients with heart failure.
October 05, 2022
Blood Volume Measurement Supports Heart Failure Patients, Studies Show
October 5, 2022 — New data presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022,…
Read More
New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure
October 04, 2022
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100 Lowers Hospital Length of Stay by 55%
October 4, 2022 — Newswise — Daxor Corporation, a global leader in blood volume measurement technology, today announces…
Read More
New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failure
October 04, 2022
New Analysis of Soloist-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
October 4, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now